A selection of articles from the 2012 issue of Turning Point.

Download this issue for your iPad from iTunes 

Download this issue for your Android-based tablet from Google Play 

To see the entire publication, please download the PDF version. If you'd like to receive a print version of Turning Point in the mail, please complete this form.

• Bridges and partnerships: Speeding delivery from lab to clinic

  When Dana-Farber decided to build a new cancer care center alongside a scientific research building, the result was a direct connection between the laboratories where new therapies are discovered and the clinics where they’re studied in patients.

• Holding promise: Targeted approaches for breast cancer treatment

  A look at the evolution of breast cancer treatment and how targeted techniques are more effective.

• Silencing the signals

  Scientists find pathways that control cell growth in endometrial and cervical cancer.

• Survivor spotlights

  Meet two women who turned to Dana-Farber for cancer treatment, and found clinical trials that allow them to continue to work – and live – as normally as possible.

• Ask the care team

  Our cancer specialists answer questions about breast and cervical cancer screenings and the difference between genetic research in people and in tumors.

• Research roundup

  New drug for ovarian cancer subtype; how cells specialize; breast cancer and Li Fraumeni syndrome; male hormone in breast tumors; strengthening genetic research.

Turning Point is published for supporters of Dana-Farber's Susan F. Smith Center for Women's Cancers. To learn more about the Susan Smith Center and its offerings, call Administrative Director Candace S. Lowe, ScD, at 617-632-2675. 

Comments, suggestions, and requests to be added to or deleted from the mailing list may be sent to:

Turning Point
Dana-Farber Cancer Institute
Department of Communications
450 Brookline Ave.
Boston, MA 02115
Phone: 617-632-4090
Email: TurningPoint@dfci.harvard.edu